Our Products

Our products support the health of patients in the areas of maternal and women's health, anemia management and cancer supportive care. More

Research & Growth

We recognize the immense value of clinical research and are committed to investing in it to expand the body of knowledge in our therapeutic areas and advance potential future health innovations for patients. More

News

AMAG Announces First Patient Enrolled in Phase 2b/3a Digoxin Immune Fab Study...

AMAG Announces First Patient Enrolled in Phase 2b/3a Digoxin Immune Fab Study Conducted by Velo Bio

WALTHAM, Mass., June 01, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that Velo Bio, LLC has enrolled the first patient More

Working at AMAG

“I enjoy being part of a company that requires a willingness to look beyond the edge of what's possible.”

Brian Plummer
Public and Governmental Affairs Manager